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ü  hMuStem cells directly 
inhibit sorted T-cell 
proliferation in a dose 
dependent manner  
ü  hMuStem cells equally inhibit 
CD4+ and CD8+ lymphocyte 
proliferation and activation in 
PBMC population 
ü  Inhibitory capacity of hMuStem 
cells is similar to those of BM-
MSC 
Inhibition of T-lymphocyte proliferation and activation 
Modulation of CD4+ T-lymphocyte subsets 
Modulation of T-modulating molecules under pro-
inflammatory conditions  
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MLR assay using T-cells as responder and allogeneic irradiated PBMC 
as stimulator cells. Statistical analysis Kruskal-Wallis test. *p<0,05 
Cytometry analysis of native or stimulated hMuStem cells (Isotype control in bright 
and membrane marker in deep colour)  
ü  hMuStem cells constitutively 
express class I MHC 
ü  hMuStem ce l l s do no t 
express the co-stimulatory 
molecules CD80 and CD86 
whatever the conditions  
Analysis of CD4+ and CD8+ cell proliferation and activation by flow cytometry (CTV and CD25 labelling 
respectively). Statistical analysis Kruskal-Wallis test. **p<0,01, ****p<0,0001 
Cytometry analysis of CD4+ T-lymphocytes subsets. Statistical analysis Mann-Whitney test. *p<0,05, **p<0,01 
ü  hMuStem cells induce formation of CD4+ IL10+ (Tr1-like) and CD4+ 
FoxP3+ (T regs-like) lymphocyte to a similar or a lesser extent that 
BM-MSC 
ü  As BM-MSC, hMuStem cells have no impact on pro-inflammatory 
IFNγ+ and IL17+ subsets 
Quantification of PGE2 and NO in hMuStem 
cells supernatant (ELISA and NO dosage). 
Statistical analysis Mann-Whitney test. *p<0,05 
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Cytometry analysis of lymphocyte proliferation (CTV labelling) 
with or without PGE2 (Indomethacin) and iNOS (L-NAME) 
inhibitors . Statistical analysis Mann-Whitney test. *p<0,05, 
***p<0,001, ****p<0,0001 
ü  iNOS inhibition partially removes the inhibitory 
effect of hMuStem cells but not those of BM-MSC 
ü  PGE2 inhibition partially removes the inhibitory 
effect of hMuStem cells. Same results was 
obtained with BM-MSC 
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ü  hMuStem cells natively secrete PGE2 
and respond to TNFα stimulation   
ü  hMuStem cells constitutively express 
iNOS, unlike BM-MSC 
ü  hMuStem cells secrete NO independently 
of pro-inflammatory stimulation 
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ü  hMuStem cells express T-cell 
inhibitory molecules PDL1 
a n d P D L 2 a f t e r p r o -
inflammatory stimulation 
ü  hMuStem cells express the 
adhesion molecule ICAM1 
a n d r e s p o n d t o p r o -
inflammatory stimulation 
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Impact of hMuStem cells on T-lymphocyte features 
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Demonstration of immunomodulatory properties for the human MuStem cell 
population, a promising candidate for cell therapy of muscular dystrophies 
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Introduction 
Over the last eighteen years, the identification of stem cells in adult tissue opened new opportunities in cell-
based therapy strategy. However, allogeneic cell transplantation protocols are highly limited by graft rejection. 
To overcome this issue, long-term immunosuppression (IS) are classically used, resulting in improved cell 
engraftment but also major adverse effects. Recently, many in vitro studies demonstrated pleiotropic 
immunomodulatory properties for adult stem cells, especially mesenchymal ones that have been shown 
to modulate the behavior of many immune cells through paracrine secretion or direct contact. These features 
could increase their ability to engraft in allogeneic recipient despite the lack of strong IS, thus 
improving their therapeutic efficiency. In addition, delivery of cells with immune privilege behavior may be 
beneficial in the context of degenerative disorders to limit chronic inflammation that characterizes tissues and 
interfere with the repair process.  
In the lab, we isolated muscle-derived stem cells (termed MuStem cells) from healthy dogs and 
demonstrated that their systemic delivery in dystrophic dogs submitted to continuous IS lead to muscle 
regeneration and long-term clinical status stabilization. Interestingly, an IS restricted to the transplantation 
period was shown to be sufficient to sustain their transplantation benefits and to prevent host immunity 
response in allogeneic context, suggesting a possible immune privilege behaviour for the hMuStem 
cells. Recently, human MuStem cells were isolated and characterized as exhibiting in vitro/in vivo myogenic 
potential, positioning them as a promising candidate for muscle-dedicated regenerative medicine.  
 
The aim of the present study is to explore the immunological-related features of hMuStem 
cells and more specifically the interaction with T-cell features and the complement system 
activation, two key effectors of allograft rejection.  
Materials & Methods 
 
 
Conclusions 
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hMuStem cell isolation and culture: Human muscle-derived cells were isolated from skeletal muscles of 9 to 15-year-old patients free of known muscle 
disease. To isolate hMuStem cells, MDC were submitted to a modified version of preplating protocol initially described by Rouger et al., 2011. hMuStem 
cells were then cultivated on coated-plastic flasks in proliferation medium containing 15% SVF, PSF and human recombinant growth factors. For pro-
inflammatory stimulation, 70% confluent cells were cultured 24 to 48h in medium supplemented with 50 ng/mL of TNFα or/and IFNγ. Four distinct batches 
of hMuStem cells were used.  
 
Lymphocyte immunosuppression assay: Either hMuStem cells or bone marrow mesenchymal stem cells (BM-MSC) were cultured with Cell Trace 
Violet (CTV)-labelled allogeneic peripheral blood mononuclear cells (PBMC) (1:10 ratio, stem cells:PBMC), during 2 to 3 days, under phytohaemagglutinin 
(PHA) stimulation. Analysis of T-lymphocyte proliferation, activation and regulatory profile were performed by flow cytometry. For inhibitory experiments, 
either Indomethacine or NG-monomethyl-L-arginine (L-NMMA) were added to the co-cultures at 0,1mM and 1mM, respectively. For Mixed Lymphoycte 
Reaction (MLR), irradiated (35Gy) hMuStem cells were added in graded ratio to human CD3+ T-lymphocytes and allogeneic irradiated PBMC co-culture. 
After 5 days, T-cell proliferation was evaluated by 3H-thymidine uptake (0,925 µBq/mL).  
 
In vitro complement-mediated hemolysis: Sheep red blood cells were incubated with 15% human serum as source of complement and (i) without 
hMuStem cell supernatant (positive control), (ii) with native hMustem cell supernatant or (iii) with Factor H-depleted hMuStem cell supernatant. Lysis of 
red blood cells was measured by OD reading at 405nm.  
 
Evaluation of hMuStem cells immune phenotype: hMuStem cell supernatants were collected after 48h of culture in native or stiumaled condition and 
stored at -20°C. Prostaglandin E2 (PGE2) and Factor H secretions were measured by ELISA, NO concentration was measured using total nitrite detection 
kit (Cayman Chemical) according to manufacturing procedures. FACS analysis was made by counting at least 15.000 events after CD55, CD59, CD80, 
CD86, ICAM1, PDL1 and PDL2 immunolabeling.  
 
 
Impact of hMuStem cells 
on complement activation 
Expression of complement-inhibitory molecules 
Inhibition of complement-mediated 
hemolysis and factor H implication 
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Cytometry analysis of native hMuStem cells (Isotype control in white 
and membrane marker in grey) 
ü  hMuStem cells express CD55 that is 
known to prevent C3 convertase assembly 
and to accelerate formed convertase 
dissociation  
1
10
100
1000
10000
100000
P
G
E
2 
se
cr
et
io
n 
(p
g/
10
6  
ce
lls
)
Native 
IFNγ-stimulated 
TNFα-stimulated
Quantification of Factor H secretion by ELISA. Hemolysis assay using 
undepleted or Factor H-depleted hMuStem cells supernatant. Statistical 
analysis Mann-Whitney test. *p<0,05 
ü  hMuStem cells secrete Facteur H that inhibits alternative 
pathway by preventing C3 convertase assembly 
ü  hMuStem cells partially inhibit complement mediated-
lysis throught Factor H secretion whom depletion results 
in hemolysis restoration 
CD59 
Schematic representation of the complement cascade that lead to MAC 
assembly and target cell destruction   
 
 
MuStem cells exhibit interesting 
immunomodulatory properties that 
could favor their efficient engraftment in 
dystrophic muscle tissue context.  
Schematic summary 
hMuStem cells are able to modulate lymphocyte feature  
 
-  By inhibiting lymphocyte proliferation under MLR activation 
-  By specifically inhibiting both CD8+ and CD4+ lymphocyte proliferation 
and activation in PBMC population  
-  By promoting T-regulatory profile 
-  hMuStem cells act on T-lymphocytes through paracrine factors 
 PGE2 secretion 
 NO production (disctinctly from BM-MSC) 
-  hMuStem cells display a membrane profile that suggest a possible 
direct interaction with lymphocyte 
 Inhibitory molecules PDL1 and PDL2 
 Adhesion molecule ICAM1 expression 
 Lack of co-stimulatory markers CD80 and CD86 expression 
hMuStem cells are able to inhibit complement pathway 
-  In a paracrine manner, by factor H secretion  
-  hMuStem cells express the complement inhibitory 
molecule CD55 and CD59 that suggest a possible 
direct impact 
 
 
CD59
Factor H
CD55
Factor H
Model for inhibitory action of complement 
cascade by hMuStem cells 
ü  hMuStem cells express CD59 that bind to 
C8 and/or C9, preventing membrane attack 
complexe (MAC) formation 
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